Etablierung eines Verfahrens zum Nachweis epigenetischer Biomarker im peripheren Blut zur Stratifizierung der Therapie des Rektumkarzinoms

Thormann, Tobias

dc.contributor.advisor	Legler, Tobias Prof. Dr.
dc.contributor.author	Thormann, Tobias
dc.date.accessioned	2015-12-08T12:05:58Z
dc.date.available	2016-12-17T23:50:05Z
dc.date.issued	2015-12-08
dc.identifier.uri	http://hdl.handle.net/11858/00-1735-0000-0028-8664-B
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-5419
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc	610	de
dc.title	Etablierung eines Verfahrens zum Nachweis epigenetischer Biomarker im peripheren Blut zur Stratifizierung der Therapie des Rektumkarzinoms	de
dc.type	doctoralThesis	de
dc.title.translated	Fully-automated hypermethylation testing by One-Step-Real-Time-PCR of 6 different potential epigenetic biomarkers in peripheral blood for rectal cancer detection and follow-up.	de
dc.contributor.referee	Legler, Tobias Prof. Dr.
dc.date.examination	2015-12-17
dc.description.abstracteng	Bisulfite treatment based assays are mainly used to detect aberrant, tumor specific methylation of specific DNA regions either from tissue or from free circulating DNA in plasma or serum. Since bisulfate based protocols are difficult to fully automate the aim of this study was to develop a rapid protocol which allows the detection and follow-up of rectal cancer from the primary blood tube. Methods: In an one step methylation sensitive, restriction enzyme based quantitative Real-Time PCR, hypermethylation in the promoter regions of RUNX3, NEUROG1, SEPT9, HLTF, TMEFF2, SDC2 and RASSF1A was investigated. Sensitivity and Specificity was evaluated after DNA-isolation-process from tumor tissue and plasma from 25 patients and 48 voluntary blood donors for each gene. The diagnostic sensitivity as well as specificity was detected from plasma was up to 20 % and 100 % for RUNX3, 12 % and 96 % for NEUROG1, 53 % and 96 % for SEPTIN9, 16 % and 96 % for TMEFF2 and 56 % and 100 % for SDC2. Sensitivity evaluated from tumor tissue-DNA by similar specificity was 87 % (RUNX3), 9 % (NEUROG1), 100 % (SEPTIN9), 91 % (TMEFF2), 87 % (SDC2) and 35 % (RASSF1A). For these results this study-analysis revealed that a fully automatable test for hypermethylated promoter regions for the detection and follow-up of solid cancer can be developed. Further results of this study are retained and will published later on.	de
dc.contributor.coReferee	Gaedcke, Jochen PD Dr.
dc.subject.ger	Ein-Schritt-Real-Time-PCR	de
dc.subject.ger	Epigenetische Biomarker	de
dc.subject.ger	Therapiestratifizierung	de
dc.subject.ger	Rektumkarzinom	de
dc.subject.ger	Restriktionsendonuklease	de
dc.subject.ger	Bisulfit-Konversion	de
dc.subject.eng	Rectal Cancer	de
dc.subject.eng	RUNX3	de
dc.subject.eng	NEUROG1	de
dc.subject.eng	HLTF	de
dc.subject.eng	SEPTIN9	de
dc.subject.eng	TMEFF2	de
dc.subject.eng	SDC2	de
dc.subject.eng	RASSF1A	de
dc.subject.eng	CpG-Island-Methylation	de
dc.subject.eng	One-Step-Real-Time-PCR	de
dc.subject.eng	Epigenetic Methylation	de
dc.subject.eng	Hypermethylation	de
dc.identifier.urn	urn:nbn:de:gbv:7-11858/00-1735-0000-0028-8664-B-1
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	Labormedizin / Klinische Chemie - Allgemein- und Gesamtdarstellungen (PPN61987564X)	de
dc.description.embargoed	2016-12-17
dc.identifier.ppn	842547517

Dateien

Name:Arbeit finale Druckversion_05.12.2015_Onlineversion_1.pdf

Größe:2.354Mb

Format:PDF

Öffnen

Name:: Arbeit finale Druckversion_05. ...
Größe:: 2.354Mb
Format:: PDF

Öffnen

Das Dokument erscheint in:

Human- und Zahnmedizin [2873]

Zur Kurzanzeige